MGD-014

N/A

Report date: 2026/03/19 16:46:50

Base Information

Drug NameMGD-014
Drug Alias NameMGD-014
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesKenya
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMacrogenics IncUniversity Of North Carolina At Chapel Hill
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A